Loading...
On August 12, 2013, the FDA approved dolutegravir (Tivicay) for treatment of HIV infection, in combination with other antiretrovirals. Like elvitegravir and raltegravir, dolutegravir is an integrase strand transfer inhibitor (INSTI); it interferes with HIV replication by binding to the integrase active site and blocking the strand-transfer step of HIV DNA integration.
The recommended dose for treatment-naive and for treatment-experienced but INSTI-naive patients (including children/adolescents aged ≥12 years and weighing ≥40 kg) is one 50-mg tablet once daily. Individuals who are taking potent UGT1A or CYP3A inducers such as rifampin, efavirenz, ritonavir-boosted fosamprenavir or tipranavir, and adults who have certa…